US Patent

US8114833 — Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices

Formulation · Assigned to Novo Nordisk AS · Expires 2025-08-13 · 1y expired

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical formulations containing a peptide and propylene glycol, used in injection devices.

USPTO Abstract

The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.

Drugs covered by this patent

Patent Metadata

Patent number
US8114833
Jurisdiction
US
Classification
Formulation
Expires
2025-08-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.